QURE Mid-Q1 '19 Update

QURE provided updated results on 2/8/19 from its upgraded hemophilia B gene therapy with the Padua Factor IX variant (AMT-061). The data continues to be impressive with these 3 patients in this dose confirmation study that has led to the start of the Ph3 study at this dose. Factor IX levels were on average 38% of normal at 12 weeks, which is above the level needed to correct severe bleeding in these patients. With the prior version of their therapy (AMT-060), FIX levels of 7% of normal were achieved at similar times and were effective to stop the need for FIX blood infusions in 8 of 9 patients. In the current study with the AMT-061 product, one patient achieved FIX levels of 51% of normal at twelve weeks. All 3 patients had been excluded from competitive trials because of pre-existing antibodies against AAV. The QURE AAV vector continues to show best in class results with respect to not eliciting an immune response even when pre-existing AAV antibodies are present. Furthermore, FIX levels are now similar to those obtained with the best competitive product of Spark/Pfizer.

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon